NRx Pharmaceuticals logo Key Points 2025 described as "extraordinarily pivotal": NRx said it is "in the FDA" with at least one drug it hopes could be approved this year and is operating revenue-generating clinics treating patients daily. Stockholders approved all four proposals, including the election of Chaim Hurvitz and Michael Taylor as Class I directors, an amendment to the 2021 Omnibus Incentive Plan, ratification of Weinberg & Company as auditor, and a non-binding say-on-pay vote. Management sa ...